<code id='C689120219'></code><style id='C689120219'></style>
    • <acronym id='C689120219'></acronym>
      <center id='C689120219'><center id='C689120219'><tfoot id='C689120219'></tfoot></center><abbr id='C689120219'><dir id='C689120219'><tfoot id='C689120219'></tfoot><noframes id='C689120219'>

    • <optgroup id='C689120219'><strike id='C689120219'><sup id='C689120219'></sup></strike><code id='C689120219'></code></optgroup>
        1. <b id='C689120219'><label id='C689120219'><select id='C689120219'><dt id='C689120219'><span id='C689120219'></span></dt></select></label></b><u id='C689120219'></u>
          <i id='C689120219'><strike id='C689120219'><tt id='C689120219'><pre id='C689120219'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:hotspot    - browse:162

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment